Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
Laurus Labs approved buying 60% of Canada-based CRO Galenvs Sciences for USD 3.75 million (₹35.63 Cr). The deal adds an oligonucleotide R&D arm and North American presence.
Laurus Labs has invested ₹107.80 Crore in its joint venture, KRKA Pharma Private Limited, through a rights issue. The company maintains its 49% stake.
Laurus Labs invested ₹12.10 Crore in Kurnool Renewables Private Limited via a rights issue, maintaining its 26% shareholding stake.